Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Omeprazole and SHR2554 in Healthy Subjects
NCT06093945Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeprumetostat in cancer, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Plasma Concentration Curve from Zero to Last Quantifiable Concentration at 48 hours and 5 more. Started Nov 2023; status: completed.
02
Drugs
zeprumetostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06093945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06093945.